Common Contracts

EX-10.1 9 d39288dex101.htm EX-10.1 EXECUTION VERSION SYNDAX PHARMACEUTICALS, INC. THIRD AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT Page - i - - ii - THIRD AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT

Investors’ Rights Agreement • May 5th, 2020 • Delaware

• Contract Type
  Investors’ Rights Agreement
• Filed
  May 5th, 2020
• Jurisdiction
  Delaware

THIS THIRD AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT (this “Agreement”) is effective as of August 21, 2015 pursuant to the amendment provisions of Subsection 7.7 of that certain Second Amended and Restated Investors’ Rights Agreement dated June 1, 2015 (the “Prior Agreement”), by and among Syndax Pharmaceuticals, Inc., a Delaware corporation (the “Company”), the investors listed on Exhibit A (each individually, an “Investor” and collectively, the “Investors”), Eckard Weber Living Trust UTA, Ronald Evans, Ph.D., Peter Ordentlich, Ph.D., Michael Downes, Ph.D. and Richard Heyman, Ph.D. (each individually, a “Stockholder” and collectively, the “Stockholders”) and Bayer Pharma AG (formerly known as Bayer Schering Pharma AG), a corporation organized under the laws of the Federal Republic of Germany (“Bayer”), and with regard to Bayer, only with respect to Subsection 2.6, Subsection 2.7 and any other provisions of this Agreement applicable thereto.

SYNDAX PHARMACEUTICALS, INC. THIRD AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT

Investors’ Rights Agreement • August 25th, 2015 • Syndax Pharmaceuticals Inc • Pharmaceutical preparations • Delaware

• Contract Type
  Investors’ Rights Agreement
• Filed
  August 25th, 2015
• Company
  Syndax Pharmaceuticals Inc
• Industry
  Pharmaceutical preparations
• Jurisdiction
  Delaware

THIS THIRD AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT (this “Agreement”) is effective as of August 21, 2015 pursuant to the amendment provisions of Subsection 7.7 of that certain Second Amended and Restated Investors’ Rights Agreement dated June 1, 2015 (the “Prior Agreement”), by and among Syndax Pharmaceuticals, Inc., a Delaware corporation (the “Company”), the investors listed on Exhibit A (each individually, an “Investor” and collectively, the “Investors”), Eckard Weber Living Trust UTA, Ronald Evans, Ph.D., Peter Ordentlich, Ph.D., Michael Downes, Ph.D. and Richard Heyman, Ph.D. (each individually, a “Stockholder” and collectively, the “Stockholders”) and Bayer Pharma AG (formerly known as Bayer Schering Pharma AG), a corporation organized under the laws of the Federal Republic of Germany (“Bayer”), and with regard to Bayer, only with respect to Subsection 2.6, Subsection 2.7 and any other provisions of this Agreement applicable thereto.